Co-Authors
This is a "connection" page, showing publications co-authored by JONATHAN M KURIE and DON LYNN GIBBONS.
Connection Strength
4.954
-
Smoking, p53 mutation, and lung cancer. Mol Cancer Res. 2014 Jan; 12(1):3-13.
Score: 0.471
-
Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev. 2009 Sep 15; 23(18):2140-51.
Score: 0.349
-
Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS One. 2009; 4(4):e5401.
Score: 0.340
-
EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer. Proc Natl Acad Sci U S A. 2023 07 11; 120(28):e2220276120.
Score: 0.227
-
p53 loss activates prometastatic secretory vesicle biogenesis in the Golgi. Sci Adv. 2021 06; 7(25).
Score: 0.197
-
Contextual cues from cancer cells govern cancer-associated fibroblast heterogeneity. Cell Rep. 2021 04 20; 35(3):109009.
Score: 0.195
-
A collagen glucosyltransferase drives lung adenocarcinoma progression in mice. Commun Biol. 2021 04 19; 4(1):482.
Score: 0.195
-
A protumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma. J Clin Invest. 2021 01 04; 131(1).
Score: 0.191
-
Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. Nat Commun. 2020 09 09; 11(1):4520.
Score: 0.187
-
Fibroblast heterogeneity and its impact on extracellular matrix and immune landscape remodeling in cancer. Matrix Biol. 2020 09; 91-92:8-18.
Score: 0.183
-
PI4KIII? is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma. Sci Transl Med. 2020 01 22; 12(527).
Score: 0.179
-
The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest. 2018 07 02; 128(7):3198.
Score: 0.161
-
The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest. 2018 04 02; 128(4):1267-1282.
Score: 0.157
-
The fibrotic tumor stroma. J Clin Invest. 2018 01 02; 128(1):16-25.
Score: 0.155
-
Epithelial-to-mesenchymal transition drives a pro-metastatic Golgi compaction process through scaffolding protein PAQR11. J Clin Invest. 2017 01 03; 127(1):117-131.
Score: 0.144
-
Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. Oncoimmunology. 2016; 5(11):e1234570.
Score: 0.142
-
Cancer-Associated Fibroblasts Induce a Collagen Cross-link Switch in Tumor Stroma. Mol Cancer Res. 2016 Mar; 14(3):287-95.
Score: 0.134
-
ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. J Clin Invest. 2014 Jun; 124(6):2696-708.
Score: 0.120
-
The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective. Cancer Manag Res. 2013; 5:187-95.
Score: 0.114
-
Fibulin-2 is a driver of malignant progression in lung adenocarcinoma. PLoS One. 2013; 8(6):e67054.
Score: 0.113
-
ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. J Clin Invest. 2012 Sep; 122(9):3170-83.
Score: 0.107
-
Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor ?2 expression. Mol Cell Biol. 2011 Nov; 31(21):4270-85.
Score: 0.100
-
The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J Clin Invest. 2011 Apr; 121(4):1373-85.
Score: 0.097
-
miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Mol Cancer Res. 2011 Jan; 9(1):25-35.
Score: 0.095
-
Distinct biological roles for the notch ligands Jagged-1 and Jagged-2. J Biol Chem. 2009 Jun 26; 284(26):17766-74.
Score: 0.085
-
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2024 Oct 23; 12(10).
Score: 0.062
-
Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer. 2022 Dec; 174:112-117.
Score: 0.054
-
The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun. 2021 12 06; 12(1):7081.
Score: 0.051
-
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
Score: 0.048
-
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020 09; 15(9):1449-1459.
Score: 0.046
-
Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol. 2020 02; 15(2):248-257.
Score: 0.044
-
Multiplatform-based molecular subtypes of non-small-cell lung cancer. Oncogene. 2017 03; 36(10):1384-1393.
Score: 0.036
-
Musashi-2 (MSI2) supports TGF-? signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. Proc Natl Acad Sci U S A. 2016 06 21; 113(25):6955-60.
Score: 0.035
-
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014 Oct 28; 5:5241.
Score: 0.031
-
Gene expression profile of A549 cells from tissue of 4D model predicts poor prognosis in lung cancer patients. Int J Cancer. 2014 Feb 15; 134(4):789-98.
Score: 0.029
-
A synthetic matrix with independently tunable biochemistry and mechanical properties to study epithelial morphogenesis and EMT in a lung adenocarcinoma model. Cancer Res. 2012 Nov 15; 72(22):6013-23.
Score: 0.027
-
Dysregulation of cell polarity proteins synergize with oncogenes or the microenvironment to induce invasive behavior in epithelial cells. PLoS One. 2012; 7(4):e34343.
Score: 0.026
-
Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer. Cancer Res. 2011 Dec 15; 71(24):7670-82.
Score: 0.025